On August 17, 2021, the U.S. Food and Drug Administration (FDA) approved a second indication for dostarlimab-gxly for the treatment of adult patients with mismatch repair deficient (dMMR) recurrent or advanced solid tumors—as determined by an FDA-approved test—that have progressed on or following prior treatment and who have no satisfactory alternative treatment options.
Read the FDA announcement.
Read GlaxoSmithKline's announcement.
Posted 8/18/2021
Understanding both the benefits to be had from offering BsAb therapy to its community and the scope of this undertaking, Vanderbilt-Ingram Cancer Center took a novel approach with its APP-led BsAb step-up dosing clinic, which won the program a 2026 ACCC Innovator Award.
